All the latest Form happenings. Want to stay in the loop? Subscribe Now
Form Bio was launched last September with an oversubscribed $30 million Series A financing round. The company’s product is a comprehensive software platform that replaces cumbersome, code-heavy bioinformatics processes with user-friendly, visual software.
Mammoth-resurrection company Colossal has spawned a digital pharma entity that wants to take cell and gene therapy to its next stage of evolution
Business model innovation in techbio, the year of microglia, big tech backs up the truck in bio, enzyme combos drive expansion of genome editing toolbox, and more.
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Claire Aldridge, Chief Strategy Officer at Form Bio.
Form Bio’s Chief Strategy Officer, Claire Aldridge, is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.
